Clinical and Basic Research on the Treatment of Polycystic Ovary Syndrome

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

126

Participants

Timeline

Start Date

December 23, 2019

Primary Completion Date

August 20, 2021

Study Completion Date

September 6, 2021

Conditions
Polycystic Ovary Syndrome
Interventions
DRUG

Zishen Qingre Lishi Huayu Granules

The treatment group used Zishen Qingre Lishi Huayu Granules, including Zhimu(Anemarrhena asphodeloides Bge.), Shengdi(Rehmannia glutinosa Libosch.), Maidong(Ophio pogon japonicus (L.f) KerGawl.) , Bixie(Dioscorea septemloma Thunb.), Huanglian(Coptis chinensis Franch.), Zhuling(Polyporus umbellatus(Pers.)Fries), Xuanshen(Scrophularia ningpoensis Hemsl.), Zelan(Lycopus lucidus Turcz. Var. Hirtus Regel), Danshen(Salvia miltiorrhiza Beg.), Gancao(Glycyrrhiza uralensis Fisch.). Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months.

DRUG

Placebo

"The treatment group used Caramel pigment、 Ku Ding Cha Extracts、Maltodextrin、Starch and 5% Zishen Qingre Lishi Huayu Granules .~Subjects take the drug from the first day of inclusion. Take 1 pack each time, bid, for 3 months."

Trial Locations (1)

Unknown

The Second Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang

All Listed Sponsors
lead

Jiangxi University of Traditional Chinese Medicine

OTHER

NCT04120597 - Clinical and Basic Research on the Treatment of Polycystic Ovary Syndrome | Biotech Hunter | Biotech Hunter